BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mollazadegan K, Welin S, Crona J. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma. Curr Treat Options Oncol 2021;22:68. [PMID: 34110508 DOI: 10.1007/s11864-021-00866-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mohamed A, Wu S, Hamid M, Mahipal A, Cjakrabarti S, Bajor D, Selfridge JE, Asa SL. Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines. Cancers (Basel) 2022;15. [PMID: 36612291 DOI: 10.3390/cancers15010295] [Reference Citation Analysis]
2 Sebesta C, Feichter A, Selimi F. Neuroendokrine Neoplasien des Gastrointestinaltrakts. Wien Med Wochenschr 2022. [DOI: 10.1007/s10354-022-00979-2] [Reference Citation Analysis]
3 Wang X, Hu S, Su F, Lin J, Duan J, Tan H, Tan H. The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review. Ann Transl Med 2022;10:1254. [PMID: 36544653 DOI: 10.21037/atm-22-4789] [Reference Citation Analysis]
4 Wu H, Yu Z, Liu Y, Guo L, Teng L, Guo L, Liang L, Wang J, Gao J, Li R, Yang L, Nie X, Su D, Liang Z. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract. Cancer Commun (Lond) 2022;42:1367-86. [PMID: 36264285 DOI: 10.1002/cac2.12372] [Reference Citation Analysis]
5 Li X, Ma Q, Chang C, Li H, Cao D. First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. Front Oncol 2022;12:958905. [DOI: 10.3389/fonc.2022.958905] [Reference Citation Analysis]
6 Bancheno WM, Adidam SR, Melaku MA. Metastatic rectal neuroendocrine carcinoma presenting with treatment-refractory immune thrombocytopenia: A case report and literature review. Medicine (Baltimore) 2022;101:e29616. [PMID: 35866784 DOI: 10.1097/MD.0000000000029616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Levy S, Verbeek WH, Eskens FA, van den Berg JG, de Groot DJA, van Leerdam ME, Tesselaar ME. First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial. Ther Adv Med Oncol 2022;14:175883592210770. [DOI: 10.1177/17588359221077088] [Reference Citation Analysis]
8 Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World J Gastroenterol 2021; 27(47): 8123-8137 [DOI: 10.3748/wjg.v27.i47.8123] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]